The La Jolla Institute for Immunology was established as an independent research center — not affiliated with a university, not subordinate to a hospital system, not primarily oriented toward drug development. This independence is rarer than it sounds. Most biomedical research happens either in academic institutions, where teaching obligations and grant structures shape what gets studied, or in pharmaceutical companies, where commercial targets determine research priorities. The LJI model of an independent, nonprofit research institute focused on a single discipline — immunology — puts it in company with places like the Salk Institute and the Weizmann Institute, institutions whose narrow focus and institutional independence have historically been productive.

The 145,000-square-foot facility on Torrey Pines Mesa occupies one of the densest concentrations of biomedical research in California. Within a few miles are the Salk Institute, the Scripps Research Institute, UCSD, the Sanford-Burnham Institute, and the Scripps Institution of Oceanography. The proximity is not accidental — the mesa's research cluster grew through deliberate decisions by institutions that recognized the value of proximity to peer organizations and to the university that trains the next generation of scientists.

Immunology is the study of how living organisms recognize and respond to threats — pathogens, cancer cells, foreign molecules — and how those responses sometimes go wrong, producing allergies, autoimmune disease, or inadequate responses to infection and cancer. It is a field of enormous practical consequence: almost every major class of disease involves the immune system in some way, and an understanding of immune mechanisms is prerequisite for designing vaccines, immunotherapies, and treatments for autoimmune conditions.

The La Jolla Institute has pursued this understanding across multiple fronts. Its researchers have studied how T cells recognize infected or cancerous cells and mount targeted responses. They have investigated the molecular mechanisms of allergic disease — building on the Ishizakas' foundational IgE work — and explored how the immune system is regulated to avoid attacking the body's own tissues. They have examined how pathogens evade immunity and how vaccination can be made more effective.

When SARS-CoV-2 emerged in 2020, the Institute rapidly organized a COVID Coronavirus Task Force, turning its immunology expertise toward understanding how the immune system responds to the novel virus. This work contributed to the broader scientific effort to characterize COVID-19 immunity — how long protective responses last, which parts of the immune response are most important, and how prior infection and vaccination interact.

One of the Institute's most prominent recent contributions came through the COVID-19 Antibody Coalition, a consortium of researchers from around the world coordinated by LJI President Erica Ollmann Saphire, who assumed leadership of the Institute in 2021. Saphire had previously led a similar international effort — the Viral Hemorrhagic Fever Immunotherapeutic Consortium — to systematically compare antibody treatments for Ebola and related viruses, identifying which antibodies worked best and understanding why.

The coalition approach is methodologically significant. Rather than having individual research groups independently characterize antibodies in ways that might not be directly comparable, Saphire's consortiums bring together samples from many institutions, test them under standardized conditions, and produce results that can be reliably compared across the full dataset. This approach requires substantial coordination and trust among competing research groups, and the fact that Saphire has been able to organize it twice — for Ebola-family viruses and for SARS-CoV-2 — reflects both the scientific value of the method and her institutional standing in the field.

The La Jolla Institute for Immunology does not make drugs or vaccines. It makes the knowledge that informs drugs and vaccines, working at the frontier of understanding how immunity actually functions — and building, from a campus above the Pacific, the scientific foundation on which medical progress depends.